Oncology
Pancreatic Cancer’s ADC Moment Will Live or Die by the Biomarker
Early ESMO GI data suggest that a CEACAM5-targeted antibody–drug conjugate may have activity in selected patients with refractory pancreatic cancer. The opportunity is real. So is the danger of treating biomarker selection as a box-ticking exercise.
Cancer Pharmacogenomics Exposes an Ancestry Gap in Routine Testing
Biomarker Testing Is Rising, But Eligibility Still Gets Lost
Colon Cancer MRD Testing Is Nearing the Access Threshold
Breast Cancer Blood Tests Could Bring Treatment Decisions Earlier
Lung Cancer Screening Now Has a Diagnostic Bottleneck
Liquid Biopsy Turns Precision Oncology Into an NHS Delivery Test
Molecular Testing Is Europe’s Real Precision Oncology Infrastructure
Cancer Approval Is No Longer Enough
Europe’s Cancer Inequality Map Becomes a Performance Test
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.